NVO Stock Is Trading Near Its 52-Week Low. Here’s Why That Number Tells Only Part of the Story.
Novo Nordisk was the most talked-about pharmaceutical company in the world not too long ago. Ozempic had evolved from a diabetes drug into a cultural icon. Wegovy was being discussed at dinner parties, in doctor’s offices, and during earnings calls. Twelve months ago, the stock was trading above $64. NVO is currently trading at about $39 on the NYSE, and the discourse surrounding it has changed significantly.
That isn’t exactly a disaster. However, it is a significant reset for a business that was briefly the most valuable in Europe in terms of market capitalization in recent years. A 52-week range of $35.12 to $64.16 indicates that investors have cooled off on the story, but they haven’t given up on Novo Nordisk. The P/E ratio has shrunk to about 10x, the market capitalization has stabilized at $132 billion, and the dividend yield, which is currently 4.59%, has subtly emerged as one of the more alluring aspects of owning the stock. When a growth stock begins to price in uncertainty, this is what occurs.
The mood was not improved by the most recent headline. On October 27, Novo Nordisk’s request to prevent Eli Lilly from running comparative ads for its weight-loss medications Zepbound and Mounjaro was denied by U.S. District Judge Zahid Quraishi in Trenton. Novo had claimed that the advertisements were deceptive and false, citing in particular commercials that contrasted higher doses of Zepbound with lower doses of Wegovy, with voiceover claims that Zepbound users lost an average of 50 pounds while Wegovy users lost only 33. The judge was unconvinced, concluding that Novo had not proven irreversible harm and that its own prescription volumes had stayed largely constant throughout the relevant time frame. It was the kind of decision that damages the narrative but doesn’t immediately alter the business.
Indianapolis-based Eli Lilly has been a fierce competitor for GLP-1 market share. Investors observing this development feel that the market for weight-loss medications was supposed to be large enough for everyone, with annual sales expected to surpass $100 billion by the end of the decade. However, the competitive landscape has proven to be more zero-sum than expected. Novo senses Lilly’s progress with Zepbound. When Q3 earnings are announced on November 4, the question is how much.
While all of this is going on, it’s important to consider what Novo Nordisk is really doing with its money. A significant share repurchase program worth up to DKK 15 billion over a 12-month period is currently underway at the company. They repurchased an additional 1.2 million B shares across daily tranches in just the five trading days that ended on October 23, averaging about 260 Danish kroner per share. During a time of price weakness, repurchasing stock is either a floor-building exercise or a sign of confidence, most likely a combination of the two. In any case, management is active.
The true turning point will be the Q3 earnings report on November 4. A year ago, Novo’s Q2 2026 revenue of about 78.5 billion Danish kroner, up just over 2% year over year, would have seemed disappointing given the rate of growth the market had anticipated. Earlier this month, the company’s next-generation weight-loss candidate, CagriSema, released new data that caused the stock to briefly rise by 2%. Even though the current competitive landscape is noisier than anticipated, there is still a pipeline story here.
With a P/E ratio of about 10 and a dividend yield of 4.59%, NVO stock might be genuinely cheap for a business with Novo’s global reach in the treatment of diabetes and obesity. It’s also possible that the market is accurately undervaluing Lilly’s persistent competition, a slower growth trajectory, and the regulatory obstacles that have been appearing more frequently in recent months. Most likely a little bit of each. It appears that November 4 will provide the clearest picture to date of which story is more important.
